Literature DB >> 15133694

Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis.

Minoru Hasegawa1, Shinichi Sato, Kazuhiko Takehara.   

Abstract

We sought to determine whether the spontaneous production of transforming growth factor-beta (TGF-beta) by peripheral blood mononuclear cells (PBMC) is increased in patients with systemic sclerosis (SSc). Culture supernatants of PBMC from SSc patients (n = 88) and healthy controls (n = 44) were analyzed by enzyme-linked immunosorbent assay. The production of active TGF-beta1 and total (active and latent) TGF-beta1 by PBMC from patients with limited cutaneous SSc (lSSc) and by PBMC from patients with diffuse cutaneous SSc (dSSc) was significantly elevated compared to the production by PBMC from normal controls. Production of active TGF-beta1 by dSSc PBMC was higher than that by lSSc PBMC, although not significantly. Patients with PBMC with increased active or total TGF-beta1 production showed significantly shorter disease duration than patients with PBMC with normal production levels. PBMC from patients without anticentromere antibody showed enhanced active TGF-beta1 production more frequently than those from patients with anticentromere antibody. PBMC from SSc patients more frequently showed enhanced total TGF-beta2 production than PBMC from normal controls. Among each leukocyte subset, spontaneous production of total TGF-beta1 was significantly higher in cultured peripheral monocytes/macrophages, but not in T cells, B cells, or NK cells, from patients than from normal controls. Thus, the enhanced production of TGF-beta by PBMC may contribute to the disease process in SSc Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133694     DOI: 10.1007/s00403-004-0472-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  10 in total

Review 1.  Transforming growth factor β--at the centre of systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

2.  Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles.

Authors:  L D Carbone; K J Warrington; K D Barrow; M Pugazhenthi; M A Watsky; G Somes; J Ingels; A E Postlethwaite
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

3.  Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension.

Authors:  Azusa Kitao; Yasunori Sato; Seiko Sawada-Kitamura; Kenichi Harada; Motoko Sasaki; Hiroyasu Morikawa; Susumu Shiomi; Masao Honda; Osamu Matsui; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

Review 4.  Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.

Authors:  Gabriela Kania; Michal Rudnik; Oliver Distler
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

Review 5.  New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Authors:  Alain Lescoat; John Varga; Marco Matucci-Cerinic; Dinesh Khanna
Journal:  Expert Opin Investig Drugs       Date:  2021-05-13       Impact factor: 6.498

6.  Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma.

Authors:  Jolanta Budzyńska-Włodarczyk; Małgorzata M Michalska-Jakubus; Małgorzata Kowal; Dorota Krasowska
Journal:  Postepy Dermatol Alergol       Date:  2016-02-29       Impact factor: 1.837

7.  Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.

Authors:  Andreea M Bujor; Fatima El Adili; Arshi Parvez; Grace Marden; Maria Trojanowska
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

8.  Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.

Authors:  Elena Schiopu; Soumya Chatterjee; Vivien Hsu; Armando Flor; Daniel Cimbora; Kaushik Patra; Wenliang Yao; Jing Li; Katie Streicher; Kathleen McKeever; Barbara White; Eliezer Katz; Jorn Drappa; Sarah Sweeny; Ronald Herbst
Journal:  Arthritis Res Ther       Date:  2016-06-07       Impact factor: 5.156

9.  Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.

Authors:  Andréa Tavares Dantas; Sayonara Maria Calado Gonçalves; Anderson Rodrigues de Almeida; Rafaela Silva Guimarães Gonçalves; Maria Clara Pinheiro Duarte Sampaio; Kamila de Melo Vilar; Michelly Cristiny Pereira; Moacyr Jesus Barreto de Melo Rêgo; Ivan da Rocha Pitta; Claudia Diniz Lopes Marques; Angela Luzia Branco Pinto Duarte; Maira Galdino da Rocha Pitta
Journal:  Dis Markers       Date:  2016-11-14       Impact factor: 3.434

10.  Periostin in Mature Stage Localized Scleroderma.

Authors:  Min-Woo Kim; Jung Tae Park; Jung Ho Kim; Seong-Joon Koh; Hyun-Sun Yoon; Soyun Cho; Hyun-Sun Park
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.